US20230025866A1 - Novel manufacturing process for gadolinium complexes - Google Patents

Novel manufacturing process for gadolinium complexes Download PDF

Info

Publication number
US20230025866A1
US20230025866A1 US17/787,545 US202017787545A US2023025866A1 US 20230025866 A1 US20230025866 A1 US 20230025866A1 US 202017787545 A US202017787545 A US 202017787545A US 2023025866 A1 US2023025866 A1 US 2023025866A1
Authority
US
United States
Prior art keywords
chelate
free
solution
dota
active carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/787,545
Other languages
English (en)
Inventor
Mikkel Jacob Thaning
Andreas Richard Meijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Assigned to GE HEALTHCARE AS reassignment GE HEALTHCARE AS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEIJER, Andreas Richard, THANING, MIKKEL JACOB
Publication of US20230025866A1 publication Critical patent/US20230025866A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Definitions

  • the present invention relates generally to a method for removal of gadolinium ion from a complex of gadolinium with DOTA.
  • the method uses active carbon to remove excess gadolinium ions.
  • a method of preparation of a Gd-DOTA magnetic resonance imaging (MRI) contrast agent comprising the inventive method of gadolinium removal.
  • Metal complexes of lanthanide metals, especially gadolinium, are of interest as MRI contrast agents in the field of in vivo medical imaging.
  • MRI contrast agents based on metal complexes of gadolinium have been reviewed extensively [see e.g. Zhang et al, Curr. Med. Chem., 12, 751-778 (2005) and Aime et al, Adv. Inorg. Chem., 57, 173-237 (2005)].
  • Free gadolinium ions can, however, exhibit significant toxicity in vivo.
  • U.S. Pat. No. 5,876,695 addresses this problem by including in the formulation of the gadolinium metal complex an additive, which is a ‘weak metal chelate complex’ such as with calcium. The idea is that the excess ‘weak metal chelate complex’ will complex efficiently any gadolinium ions which may adventitiously be either liberated or present, and thus improve the safety of the MRI contrast composition.
  • Reference Example 3 of EP 2242515 B9 includes a laboratory scale preparation which prepares Gd-DOTA by reaction of DOTA (10 g, 25 mmol) with a stoichiometric amount of gadolinium oxide (Gd 2 O 3 , 12.5 mmol) at 80° C. in water at pH 6 to 7 maintained with NaOH. The pH is then adjusted with HCl to 5, and residual free gadolinium removed by stirring with a Chelex resin in sodium ion form for 2-hours, followed by filtration.
  • EP 2242515 B9 teaches that the Gd-DOTA complex is then precipitated from aqueous ethanol giving an 80% isolated yield of sodium gadoterate as a white powder.
  • EP 2242515 B9 does not teach how the method of Reference Example 3 can be adapted to provide the liquid pharmaceutical composition having an excess of macrocyclic chelator in the range 0.002% and 0.4% mol/mol, in particular on an industrial scale.
  • Example 3 of EP 2242515 B9 provides the product in sodium salt form unless further purification steps are carried out.
  • Example 3 of EP 2242515 B9 also describes the preparation of a specific gadolinium complex which necessitates purification and isolation steps unsuitable for an industrial manufacturing process of preparation of a liquid pharmaceutical formulation.
  • WO 2016/083597 discloses a process for preparation of a liquid pharmaceutical formulation comprising a metal complex of a lanthanide metal with a macrocyclic chelator which includes a step of removal of the excess lanthanide by contacting one or more times with a scavenger resin, whereby the excess lanthanide is complexed to said scavenger resin
  • the method described in WO 2016/083597 can be carried out on an industrial scale. It avoids the need for measurement and adjustment steps as the lanthanide chelator metal complex is obtained without excess lanthanide ions being present by using a solid-phase bound scavenger chelator. Since this process provides an intermediate solution of the lanthanide metal complex without free lanthanide ions, the amount of excess macrocyclic chelator to add to give the desired formulation having a defined excess of free chelator can be calculated readily.
  • the present invention relates to a method comprising the following steps:
  • the present invention relates to a method comprising the following steps:
  • the present invention provides a method of preparation of an MRI contrast agent which comprises:
  • the present invention provides a solution of Gd-chelate free from excess [Gd free ] obtainable by a method comprising steps (i)-(iii) as defined herein.
  • the present invention provides a liquid pharmaceutical formulation comprising Gd-chelate, together with chelate in uncomplexed form obtainable according to the method comprising steps (A) and (B) as define herein.
  • the present invention provides an MRI contrast agent obtainable according to the method comprising steps (a)-(d) as defined herein.
  • active carbon is capable of the efficient removal of free gadolinium ions from a Gd-DOTA meglumine solution.
  • the method of the present invention represents a relatively inexpensive and uncomplicated method for the production of Gd-chelates as compared with known methods.
  • active carbon treatment is an efficient method for removal of gadolinium ions in a gadoteric acid meglumine solution at a concentration and pH range that is representative of gadoterate meglumine manufacturing conditions.
  • the method of the present invention furthermore represents a significant simplification of previous methods (e.g., see WO 2016/083597) as the preconditioning steps of the scavenger resin are not required.
  • FIG. 1 shows the distribution of Gd 3+ hydrolytic species in 0.1M LiCl at 298K.
  • c Gd 1.00 mM. (from Djurdjevic et al. Acta. Chim. Slov. 2010, 386-397)
  • FIG. 2 depicts gadolinium concentration [Gd] in spiked 0.5M Gd-DOTA solutions after titration.
  • FIG. 3 illustrates the effect of active carbon treatment.
  • the magnified graph is included for clarity on low gadolinium concentration [Gd] samples.
  • FIG. 4 shows CAD chromatograms of selected active carbon treated samples. *DOTA elutes as copper complex.
  • FIG. 5 shows the absorbance ratio vs. gadolinium concentration [Gd] for a representative calibration curve.
  • paramagnetic metal ions such as gadolinium are administered as metal chelates in order to avoid any toxic effects of these metal ions in their free form.
  • the geometry of the chelate should be such that the paramagnetic effectiveness of the metal ion is maintained.
  • a “chelate” (also the term “cheland” is used to define the chelate without the metal) in the context of the present invention is any ligand capable of producing a highly stable metal chelate complex, e.g. one with a thermodynamic stability constant of at least 10 12 .
  • the chelate can be a linear, cyclic or branched chelating agent, e.g.
  • the chelate will be a polyaminopolyoxyacid (e.g. polyaminopolycarboxylic acid).
  • the chelate is selected from the group comprising the following (or derivatives thereof): diethylenetriaminepentaacetic acid (DTPA); 4-carboxy-5, 8, 11-tris(carboxymethyl)-1-phenyl-2oxa-5, 8, 11-triazatridecan-13-oic acid (BOPTA); 1, 4, 7, 10-tetraazacyclododecan-1, 4, 7-triactetic acid (DO3A); 1, 4, 7, 10-tetraazacydododecan-1, 4, 7, 10-tetraactetic acid (DOTA); ethylenediaminotetraacetic acid (EDTA); 10-(2-hydroxypropyl)-1, 4, 7, 10-tetraazacydododecan-1, 4, 7-triacetic acid (HP-DO3A); 2-methyl-1, 4, 7, 10-tetraazacyclododecan-1, 4, 7, 10-tetraacetic acid (MCTA); tetramethyl-1, 4, 7, 10-tetraazacydododecan-1
  • DTPA
  • the chelate is selected from DTPA, DOTA or derivatives thereof. In a yet further embodiment said chelate or derivative thereof is selected from EOB-DTPA, DTPA-BMA, DTPA-BMEA, DTPA, DOTA, BOPTA, HP-DO3A and BT-DO3A. In one embodiment the chelate is DOTA.
  • chelate in uncomplexed form and chelate “free of coordinated gadolinium ions” and “free chelate” refers to any of the above-described chelates of the invention with no gadolinium co-ordinated thereto.
  • DOTA in uncomplexed form has the following structure:
  • a “complex of gadolinium with chelate” refers the chelate including the co-ordinated metal.
  • glycoside salt of Gd-DOTA or “meglumine salt of Gd-DOTA chelate” refers to the following:
  • active carbon also commonly referred to as activated carbon, charcoal, activated powder, carbon black, Carboraffin, Carborafine
  • active carbon refers to any active carbon known in the art including active carbon as a form of carbon processed to have small, low-volume pores to provide a large surface area.
  • Active carbon may be provided as particles, pellets or as a mesh all of which are readily available commercially.
  • active carbon mesh 100 is active carbon mesh 100 from Sigma Aldrich (161551-175-D).
  • Active carbon is commonly used on a laboratory scale to purify solutions of organic molecules containing unwanted coloured organic impurities. Filtration over activated carbon is well-known in large scale fine chemical and pharmaceutical processes for the same purpose.
  • purification refers to the process(es) to obtain a substantially gadolinium ion-free version of the desired product, i.e. Gd-chelate with [Gd free ] removed.
  • the term “substantially” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result.
  • the term “substantially pure” herein encompasses Gd-chelate with zero [Gd free ] as well as Gd-chelate where only minute quantities of [Gd free ] remain such that any subsequent steps can be successfully carried out.
  • free from excess [Gd free ] herein can be understood to be synonymous with “substantially pure”.
  • free gadolinium ions or “[Gd free ]” refers to Gd 3+ in solution that is not complexed with chelate.
  • complexation refers to the process by which a metal ion (here gadolinium ion) is bound through multiple ligands of a chelating agent.
  • suitable solvent refers to any solvent or solvent system in which the complexation of chelate with gadolinium can take place.
  • Water is an example of a suitable solvent, with water for injection (WFI) being particularly suitable.
  • contacting in the context of contacting a reaction solution with active carbon can be taken to mean addition of the solution to the active carbon or addition of active carbon to the solution.
  • addition of the solution to the active carbon is carried out by passing the solution through a column or cartridge containing the active carbon, optionally where the flow of solution through the column is facilitated by use of a pump.
  • one or more times can encompass one or several contact steps as required to reduce the concentration of gadolinium ions to the desired level. Ideally fewer times is better.
  • separation refers to the physical removal of the active carbon from the solution. In one embodiment separation is carried out by filtration. In certain embodiments separation is carried out after each contacting step. Where the active carbon is contained in a column separation is automatically achieved as the solution passed out of the column. Nevertheless, where active carbon is contained in a column, the method of the invention may include a separate separation step whereby any fine particles of active carbon that may be present are removed.
  • a “pharmaceutical formulation” can be understood to be a composition of Gd-chelate or a salt or solvate thereof together with a biocompatible carrier in a form suitable for mammalian administration.
  • the “biocompatible carrier” is a fluid, especially a liquid, in which Gd-chelate is dissolved, such that the resulting composition is physiologically tolerable, i.e. can be administered to the mammalian body without toxicity or undue discomfort.
  • a form suitable for mammalian administration is meant a composition which is sterile, pyrogen-free, lacks compounds which produce toxic or adverse effects, and is formulated at a biocompatible pH.
  • Such compositions lack particulates which could risk causing emboli in vivo, and are formulated so that precipitation does not occur on contact with biological fluids (e.g. blood).
  • Such compositions also contain only biologically compatible excipients, and are preferably isotonic.
  • the pharmaceutical formulation is suitable for use as an “MRI contrast agent”, i.e. to carry out MRI of the human and non-human animal body.
  • the pharmaceutical formulation comprises one or more pharmaceutically-acceptable excipients. These suitably do not interfere with the manufacture, storage or use of the final composition.
  • suitable pharmaceutically-acceptable excipients include buffering agents, stabilizers, antioxidants, osmolality adjusting agents, pH adjusting agents, excess free chelate and weak complexes of physiologically tolerable ions.
  • suitable excipients will be well known to those of skill in the art and are further described in e.g. WO1990003804, EP0463644-A, EP0258616-A and U.S. Pat. No.
  • the pharmaceutical formulation of the invention in one embodiment is in a form suitable for parenteral administration, for example injection.
  • the pharmaceutical formulation may therefore be formulated for administration using physiologically acceptable excipients in a manner fully within the skill of the art.
  • Gd-chelate optionally with the addition of pharmaceutically acceptable excipients, may be suspended or dissolved in an aqueous medium, with the resulting solution or suspension then being sterilized.
  • a non-limiting example of a suitable buffering agent is tromethamine hydrochloride.
  • excess free chelate (also can be referred to as “excess cheland” or “free ligand”) is defined as any compound capable of scavenging free gadolinium ion.
  • the presence of excess free chelate ensures that no free gadolinium will be formed during the certified shelf life of the product. Degradation of a gadolinium-containing ligand can in principle lead to free gadolinium and excess free chelate will complex liberated gadolinium ions and ensure zero concentration of free Gd.
  • the amount of excess free chelate in a paramagnetic chelate formulation is selected that can act as a gadolinium scavenger to reduce or prevent release of gadolinium during its shelf life and from the formulation in vivo post injection.
  • the optimal amount of free chelate will result in a pharmaceutical formulation having suitable physicochemical properties (i.e. viscosity, solubility and osmolality) and avoiding toxological effects such as zinc depletion in the case of too much free chelate.
  • excess free chelate is as defined hereinabove for “chelate in uncomplexed form”. In one embodiment of the present invention excess free chelate is DOTA in uncomplexed form. Where DOTA is used as excess free chelate in one embodiment it is present in the range 0.002 and 0.4 mol/mol %.
  • a “physiologically tolerable ion” may in one embodiment be selected from calcium salts or sodium salts such as, for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate.
  • Parenterally administrable forms should be sterile and free from physiologically unacceptable agents and should have low osmolality to minimize irritation or other adverse effects upon administration and thus the pharmaceutical composition should be isotonic or slightly hypertonic.
  • composition of the invention for the pharmaceutical composition of the invention to be administered parenterally, i.e. by injection its preparation further comprises steps including removal of organic solvent, addition of a biocompatible buffer and any optional further ingredients such as excipients or buffers.
  • steps to ensure that the pharmaceutical composition is sterile and apyrogenic also need to be taken.
  • Sterility can be achieved using “aseptic manufacturing conditions”, i.e. where sterility is maintained throughout the manufacturing process.
  • terminal sterilisation can be used, i.e. where a final step assuring sterility of the product is carried out.
  • “Pharmaceutically acceptable containers or syringes” suitably assure patient safety, the efficacy of the pharmaceutical formulation through the intended shelf life, uniformity of the pharmaceutical formulation through different production lots, control of possible migration of packaging components into the pharmaceutical formulation, control of degradation of the pharmaceutical formulation by oxygen, moisture, heat, etc., prevention of microbial contamination, sterility, etc.
  • Suitable containers and syringes can be made from pharmaceutically acceptable glass or plastic.
  • An exemplary plastic bottle is the PluspakTM.
  • ambient temperature herein can be taken to mean any temperature between about 18-30° C.
  • the target [Gd free ] is in the range 0.1-0.9 mM, in one embodiment 0.2-0.85 mM, in another embodiment 0.32-0.83 mM. In one embodiment the concentration of free gadolinium ions in the product following contact with active carbon endpoint is not more than 1.8 ⁇ g/mL.
  • said Gd-chelate is selected from; gadoterate (Dotarem), gadodiamide (Omniscan), gadobenate (MultiHance), gadopentetate (Magnevist), gadoteridol (ProHance), gadofosveset (Ablavar, formerly Vasovist), gadoversetamide (OptiMARK), gadoxetate (Eovist or Primovist) and gadobutrol (Gadavist).
  • said chelate is a macrocyclic chelate. In one embodiment said macrocyclic chelate is DOTA. In one embodiment said Gd-chelate is gadoterate. In one embodiment said Gd-chelate is gadoterate meglumine.
  • the excess gadolinium of step (i) is 0.001 to 5 mol/mol %.
  • the pH is adjusted to 4.5 to 7.0, for example 4.5 to 6.5.
  • said Gd-chelate is gadoterate meglumine and said pH is adjusted using meglumine.
  • said amount of active carbon per millilitre of first solution is 200-400 mg/ml, in one embodiment 100-200 mg/ml and in another embodiment 10-20 mg/ml.
  • said active carbon is in the form of powder or particles, or alternatively it may be shaped or incorporated into other forms, e.g. pellets, discs or a mesh. Where active carbon is shaped into other forms, it may be held together by a binding agent, e.g. cellulose.
  • said active carbon is in the form of particles.
  • said active carbon is packed into a column or cartridge.
  • the active carbon may be in any of the forms described herein.
  • the active carbon is supported by a scaffold within the column, which can be useful for active carbon shaped or incorporated into forms as described above.
  • the column is a housing wherein active carbon is present as one or more stationary discs made from active carbon held together by a cellulose binding agent.
  • step (ii) is carried out at ambient temperature.
  • Gd-chelate for preparation of a liquid pharmaceutical formulation comprising Gd-chelate, together with chelate in uncomplexed form according to an aspect of the present invention
  • said Gd-chelate is Gd-DOTA and said chelate is DOTA and said DOTA in uncomplexed form is in an amount in the range 0.002 and 0.4 mol/mol % of said Gd-DOTA.
  • the DOTA in uncomplexed form is in an amount in the range 0.025 and 0.25 mol/mol %.
  • the DOTA uncomplexed form is free of coordinated gadolinium ions and comprises less than 50 ppm M wherein M is a metal ion chosen from calcium, magnesium and zinc, or mixtures thereof.
  • a meglumine Gd-DOTA liquid bulk solution was diluted to 0.5M (Gd-DOTA) using water, followed by addition of gadolinium ions (gadolinium chloride) to form a gadolinium spiked meglumine Gd-DOTA solution.
  • the obtained solution was theoretically 0.5M (with respect to [Gd-DOTA]) and the concentration of excess free gadolinium ions was determined to be 1.4 mM, according to spectrophotometric analysis.
  • the pH drops from 7.3 to 4.8 during addition of gadolinium ions to the Gd-DOTA solution (Scheme 1 above). This drop in pH ensures that the spiked gadolinium ions indeed are in a free ionic form as it is known that gadolinium ions will form hydrolytic species with hydroxide ions at pHs from 6 and higher ( FIG. 1 ), that eventually will form insoluble gadolinium hydroxide; Gd(OH) 3 .
  • FIG. 3 compares the [Gd] free of the spiked Gd-DOTA solution prior to active carbon treatment (NT; not treated) to solutions treated with 0.01-0.2 g/mL of active carbon, after 10 and 50 minutes of contacting time.
  • the data indicate that as little as 0.02 g/mL of active carbon is capable of reducing the concentration of free gadolinium from 1.4 mM to roughly 0.02 mM.
  • the 0.01 g/mL sample showed a lower [Gd] after 50 min compared to 10 min, it is not known if the system had reached equilibrium at this point or if further adsorption is possible. The rest of the samples (>0.01 g/mL) had reached equilibrium after the first time point, indicative of an excessive active carbon load.
  • the pH is affected slightly by the active carbon treatment, however still well within acceptable ranges with respect to process requirements and solubility of gadolinium ions ( FIG. 2 ).
  • HPLC-CAD-MS analysis of active carbon treated samples indicate that no new compounds are formed due to degradation or chemical incompatibility (as illustrated in FIG. 4 ). Besides minor impurities introduced by the active carbon (small amounts of sodium and an unidentified impurity) or the spiking operation (chloride ions) no new peaks were found.
  • Example 1 is a comparative example describing a known method to remove free Gd ions from a meglumine Gd-DOTA solution.
  • Example 2 is a method of the invention for removal of free Gd ions from a meglumine Gd-DOTA solution.
  • DOTA (211 kg) was dissolved in boiling water (1600 kg) and Gd 2 O 3 was added (94.8 kg). The temperature was set to 70° C. and the slurry was stirred over-night. The presence of free gadolinium ions (1390 ug/g) in the solution was determined by colorimetric titration.
  • the temperature was adjusted to 50° C. and meglumine was added to achieve pH 5.5 in the solution. Initially 94.8 kg meglumine was added and the final adjustment of the pH was made with an aqueous solution of meglumine (1.5 M).
  • Scavenger resin (Puropack C150, 50 L) was conditioned to proton form according to standard procedures. The resin was rinsed with water until neutral water was eluted from the resin bed. A solution of meglumine (400 g/kg resin) was cycled through the resin bed for 10 h and the resin was again rinsed to neutral pH with water.
  • the megluminized resin was placed in a column and the Gd-DOTA solution was pumped through the column at a flow rate sufficient to pass the entire volume of solution in 2 h.
  • the concentration of free gadolinium (45 ug/ml) was determined using colorimetric spectrophotometry.
  • the ion exchange of the meglumine Gd-DOTA solution was continued with one more passage through the column to establish a level of free gadolinium below detection limit by colorimetric titration (4 ug/g), to give a Gd-DOTA-meglumine solution.
  • GdCl 3 solution was prepared from 1.86 g GdCl 3 hexahydrate dissolved in 10 mL deionized water.
  • concentration of gadolinium ([Gd]) was determined using a spectrophotometric method.
  • Gd spiked (1.4 mM) meglumine Gd-DOTA solution prepared from 50 mL of liquid bulk ClariscanTM meglumine Gd-DOTA to which was added 0.6 mL of GdCl 3 (0.44M) followed by dilution to 100 mL using DIW. The solution was then allowed to stand for >72 h before use in experiments to allow for complete complexation.
  • Gd spiked (1.8 mM) meglumine Gd-DOTA solution was added 0.1, 0.2, 0.3, 0.4, 0.5, 1 or 2 g active carbon (mesh 100, Sigma Aldrich, 161551-175-D). Suspensions were placed in a shaking block and samples were taken after 10 and 50 minutes. All samples were filtered on Acrodisc nylon membranes and analyzed for [Gd] and HPLC purity (pH was measured in the suspension).
  • HPLC analysis was performed on an Agilent Acquity UPLC system equipped with a Diode Array Detector, a Waters Premier TOF mass spectrometer and a Dionex Charged Aerosol Detector.
  • the concentration of free gadolinium was determined using a slightly modified published method (Barge, A; Contrast Media & Molecular Imaging, 2006, 184-8), based on the differences in the visible spectra of free and complexed Xylenol orange.
  • the absorbance ratio of wavelengths 573 and 433 nm is proportional to the [Gd] in the 0 to 0.1 mM range ( FIG. 5 ). At higher ranges, the absorbance ratio deviates from linearity and shows a more complex relationship with [Gd]. All measured samples were therefore diluted to fit the 0-0.1 mM calibration range.
  • GdCl 3 standard solutions were prepared from GdCl 3 hexahydrate and serial dilutions using 50 mM HOAc buffer.
  • HOAc 50 mM HOAc was buffer prepared by adding 0.72 mL HOAc (conc.) to 200 mL deionized water, adjusting pH to 5.9 using 1M NaOH, then diluting to 250 mL using deionized water.
  • Xylenol Orange solution prepared by dissolving 2 mg Xylenol Orange in 100 mL 50 mM HOAc (pH 5.9) buffer.
  • Spectrophotometric sample preparation To 25 ⁇ L of sample solution was added 975 ⁇ L Xylenol Orange solution.
  • DOTA (370 kg (range: 310-410 kg)) was dissolved in boiling water (2000 kg) and Gd 2 O 3 (162.8 kg range: 135-190 kg)) was added. The temperature was set up to 80° C. and stirred over-night. The presence of free gadolinium ions was determined by colorimetric titration.
  • the temperature of solution Gd-DOTA meglumine was further adjusted to 40° C. 4 modules of MCN active carbon were placed in series. The first 3 filter houses contained 1.01 kg active carbon and the last one contained 2.7 kg of active carbon. MCN active carbon preconditioned before the Gd-DOTA meglumine solution was pumped. The MCN active carbon was rinsed with water until it reached conductivity below 10 ⁇ S/cm. The GdDOTA solution was pumped through the 4 series of active carbon at a flow rate of 800-1000 liter/m 2 ⁇ hr. The concentration of free gadolinium was determined using calorimetric titration. The GdDOTA solution after passing the active carbon establish a level of free gadolinium below detection limit by colorimetric titration (1.8 ⁇ g/ml) to give a Gd-DOTA meglumine solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
US17/787,545 2019-12-20 2020-12-18 Novel manufacturing process for gadolinium complexes Pending US20230025866A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1919073.5A GB201919073D0 (en) 2019-12-20 2019-12-20 Novel manufacturing process
GB1919073.5 2019-12-20
PCT/EP2020/087323 WO2021123383A1 (fr) 2019-12-20 2020-12-18 Nouveau procédé de fabrication de complexes de gadolinium

Publications (1)

Publication Number Publication Date
US20230025866A1 true US20230025866A1 (en) 2023-01-26

Family

ID=69322685

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/787,545 Pending US20230025866A1 (en) 2019-12-20 2020-12-18 Novel manufacturing process for gadolinium complexes

Country Status (11)

Country Link
US (1) US20230025866A1 (fr)
EP (1) EP4077284A1 (fr)
JP (1) JP2023506957A (fr)
KR (1) KR20220116204A (fr)
CN (1) CN114845999A (fr)
AU (1) AU2020405352A1 (fr)
BR (1) BR112022009480A2 (fr)
CA (1) CA3164951A1 (fr)
GB (1) GB201919073D0 (fr)
MX (1) MX2022007601A (fr)
WO (1) WO2021123383A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
CA1335819C (fr) * 1988-09-27 1995-06-06 William Phillip Cacheris Chelate metallique contenant un milieu contrastant pour l'imagerie diagnostique
EP0436579B1 (fr) 1988-09-27 1993-08-04 Nycomed Salutar, Inc. Compositions de chelates
DE19507820A1 (de) * 1995-02-21 1996-08-22 Schering Ag Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
US20030050452A1 (en) * 2000-12-26 2003-03-13 Yuji Hashiguchi Process for producing metal complex of aminooligosaccharide derivative
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
CA2833659C (fr) * 2011-04-21 2019-12-03 Bayer Intellectual Property Gmbh Preparation de gadobutrol de purete elevee
GB201421161D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
GB201421162D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
KR102464647B1 (ko) * 2016-11-28 2022-11-08 바이엘 파마 악티엔게젤샤프트 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물

Also Published As

Publication number Publication date
CN114845999A (zh) 2022-08-02
WO2021123383A1 (fr) 2021-06-24
EP4077284A1 (fr) 2022-10-26
MX2022007601A (es) 2022-07-19
JP2023506957A (ja) 2023-02-20
CA3164951A1 (fr) 2021-06-24
BR112022009480A2 (pt) 2022-07-26
AU2020405352A1 (en) 2022-08-11
KR20220116204A (ko) 2022-08-22
GB201919073D0 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
US11186553B2 (en) Metal complex formulations
US20220354971A1 (en) Lanthanide complex formulations
US10314927B2 (en) Formulations of metal complexes
US20230339945A1 (en) Method for preparing a chelating ligand derived from pcta
KR102502862B1 (ko) 가돌리늄과 부분입체이성질체적으로 풍부한 pcta로부터 유래된 킬레이트화 리간드의 착물, 및 제조 및 정제 공정
US20230025866A1 (en) Novel manufacturing process for gadolinium complexes
Balogh et al. Kinetics of formation and dissociation of lanthanide (iii) complexes with the 13-membered macrocyclic ligand TRITA 4−
RU2806027C2 (ru) Диастереоизомерно обогащенный комплекс гадолиния и хелатирующего лиганда на основе pcta, способ его получения и очистки
US20210371437A1 (en) Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process

Legal Events

Date Code Title Description
AS Assignment

Owner name: GE HEALTHCARE AS, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THANING, MIKKEL JACOB;MEIJER, ANDREAS RICHARD;REEL/FRAME:060252/0943

Effective date: 20200206

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION